The Differences in Clinical Outcomes for Unresectable Huge (≥ 10 cm) Hepatocellular Carcinoma With Portal Vein Thrombosis Treated by Two Different Radiotherapy Techniques
Cancer Medicine · 2026-05 · 15 (5)
DOI: 10.1002/cam4.71926 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Cancer Medicine, online erschienen am 12.05.2026. Verfasst von ZengLiang Huang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Interventional Ward of the Radiology Department, 900th Hospital of PLA, Fuzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Portal Vein, Venous Thrombosis. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Aims
To explore a safe and effective treatment modality for unresectable huge (≥ 10 cm) hepatocellular carcinoma with portal vein thrombosis. And to provide more data on the synergistic antitumor effects of radiotherapy combined with immune checkpoint inhibitors and antiangiogenic therapy. Materials and Methods This study compared the clinical outcomes in 63 patients with unresectable huge hepatocellular carcinoma and portal vein thrombosis who were treated with either γ‐ray body radiotherapy or linear accelerator radiotherapy (the RTγ and RTa groups, respectively), both combined with immune checkpoint inhibitors and antiangiogenic therapy.
Results
The median progress‐free survival (PFS) and median overall survival (OS) in the RTγ group were 12.1 and 14.3 months, respectively. And those in the RTa group were 6.6 and 8.1 months, respectively. The 1‐, 2‐, and 3‐year PFS were 43.2%, 24.3%, 10.8% in the RTγ group and 11.5%, 3.8%, 0% in the RTa group, respectively. The OS at the same intervals were 56.7%, 40.5%, and 18.9% in the RTγ group, and those were 23.1%, 7.7%, and 0% in the RTa group, respectively. The percentage of normal liver volume (NLV) in whole liver volume (WLV) > 60% and negative viral infection are significant independent factors for superior PFS and OS. Severe radiation‐induced liver disease was observed in 23.1% ( n = 6) of patients in the RTa group, compared to none in the RTγ group.
Conclusions
RTγ combined with immune checkpoint inhibitors and antiangiogenic therapy is an effective and safe treatment modality for unresectable huge hepatocellular carcinoma with portal vein thrombosis. An NLV/WLV ratio > 60% and negative viral infection independently predicted better PFS and OS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interventional Ward of the Radiology Department, 900th Hospital of PLA, Fuzhou, China.
- Department of Tumor Radiotherapy, 900th Hospital of PLA, Fuzhou, China.
Zitieren
APA
Huang, Z., Chen, Z., Shen, J., Lin, J., Den, S., & Zhong, N. (2026). The Differences in Clinical Outcomes for Unresectable Huge (≥ 10 cm) Hepatocellular Carcinoma With Portal Vein Thrombosis Treated by Two Different Radiotherapy Techniques. Cancer Medicine, 15(5). https://doi.org/10.1002/cam4.71926
Vancouver
Huang Z, Chen Z, Shen J, Lin J, Den S, Zhong N. The Differences in Clinical Outcomes for Unresectable Huge (≥ 10 cm) Hepatocellular Carcinoma With Portal Vein Thrombosis Treated by Two Different Radiotherapy Techniques. Cancer Medicine. 2026;15(5). doi:10.1002/cam4.71926
BibTeX
@article{Huang2026,
author = {Huang, ZengLiang and Chen, ZhongHua and Shen, JuanJuan and Lin, JianHai and Den, ShiLong and Zhong, NanBao},
title = {The Differences in Clinical Outcomes for Unresectable Huge (≥ 10 cm) Hepatocellular Carcinoma With Portal Vein Thrombosis Treated by Two Different Radiotherapy Techniques},
journal = {Cancer Medicine},
year = {2026},
volume = {15},
number = {5},
doi = {10.1002/cam4.71926}
}
EUVIMED